Industrializing drug discovery on more than fifty petabytes of multimodal biological and chemical data.
Recursion Pharmaceuticals
venture active confidence: Medium status: Draft updated 2026-07-14
Summary
Salt Lake City-based Recursion combines automated biology, large datasets, machine learning, and clinical development to industrialize drug discovery. If its platform reliably finds better targets and compresses discovery across many diseases, it could move the global frontier rather than merely produce one drug.
Impact
The available evidence suggests Recursion matters because it is attacking one of the largest bottlenecks in medicine: the cost, time, and failure rate of discovering new drugs. Recursion's own mission page says traditional discovery often takes more than a decade, costs around $2 billion, and sees roughly 90 percent of drugs fail in clinical trials.
The impact case is strongest if Recursion's platform helps identify better targets, compress early discovery, or gives partner pharma companies a better map of disease biology. The harder-to-prove claim is clinical translation: impressive cellular and computational systems still have to become medicines that work in patients.
What They Are Building
Recursion is building a data and experimentation platform for drug discovery. Public materials emphasize phenomics, transcriptomics, proteomics, ADME, de-identified patient data, automated labs, precision chemistry, and BioHive-2, which Recursion describes as the most powerful supercomputer in pharma.
The available public framing makes Recursion relevant to machine learning engineers, computational biologists, wet-lab scientists, and platform builders who want to work on real experiments at machine scale rather than thin AI wrappers around literature search.
What They Need Now
Hiring spans computational biology (early discovery, oncology, neuroscience), clinical pharmacology and clinical science, CMC/regulatory affairs, DMPK leadership, compound management, and corporate strategy. Broader fit still includes ML infrastructure engineers, assay development scientists, medicinal chemists, clinical operators, and product-minded platform leaders who can serve both internal programs and pharma partners.
For a match engine, Recursion is most relevant to candidates who want a scaled organization, public-company rigor, and a serious AI-biology interface. It may be less ideal for someone who wants very early startup ambiguity or full control over scientific direction.
Who Could Help
Useful helpers include translational medicine advisors, clinical trial operators, pharma partnership builders, computational biology leaders, platform product executives, and legal or regulatory specialists who understand data-rich drug development.
The company may also be a useful reference point for researchers commercializing biology tools: even if Recursion is not the right partner, its public model helps explain what a scaled AI-biology platform requires.
Utah Context
Recursion is headquartered in downtown Salt Lake City and is a visible anchor for Utah's life-sciences and AI community. Its presence gives the state a credible example that advanced biology, compute infrastructure, and public-market ambition can coexist outside the Boston and Bay Area biotech centers.
Evidence
Open Questions
- Which Recursion programs are currently the strongest evidence that platform discovery is translating into clinical value?
- How much of Recursion's current impact will come from internal pipeline assets versus partner use of the platform?